Kiniksa Pharmaceuticals, Ltd. (KNSA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Hamilton, Bermuda. The current CEO is Sanj K. Patel.
KNSA has IPO date of 2018-05-25, 315 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.48B.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company's product portfolio includes ARCALYST, an approved treatment for recurrent pericarditis, along with several clinical-stage candidates including Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 targeting immune-mediated disorders. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa is committed to addressing serious inflammatory and immunological conditions with limited existing treatment options.
